Agios Pharmaceuticals reported $1.06M in Loan Capital for its fiscal quarter ending in September of 2022.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
Astellas Pharma JPY 320B 0 Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
Bayer EUR 32.71B 1B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Novartis USD 24.24B 174M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025